Expert Interview
A Third View: Gaining insight into the roll out of Journavx (suzetrigine) which was recently approved as a non-opioid treatment for acute pain.
Ticker(s): VRTXInstitution: Health Partners
- Medical Director | Interventional Pain Physician at HealthPartners with experience in anesthesiology and pain medicine practice
- Skilled at providing clinical care and developing tailored treatments to diverse patients in various medical settings
- Clinical Experience include Clinical Pain Management, Image Guided Interventions, Pain Neuroscience Education, Opioid-Sparing Medication Management
- Manages 100 patients weekly with acute and chronic pain
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
